| Identification | Back Directory | [Name]
Nitracrine | [CAS]
4533-39-5 | [Synonyms]
Nitracrine
3-(dimethylamino)propyl-(1-nitroacridin-9-yl)amine
N',N'-dimethyl-N-(1-nitroacridin-9-yl)propane-1,3-diamine
1,3-Propanediamine, N1,N1-dimethyl-N3-(1-nitro-9-acridinyl)- | [Molecular Formula]
C18H20N4O2 | [MDL Number]
MFCD00866469 | [MOL File]
4533-39-5.mol | [Molecular Weight]
324.38 |
| Chemical Properties | Back Directory | [Melting point ]
134-135° | [Boiling point ]
462.71°C (rough estimate) | [density ]
1.2155 (rough estimate) | [refractive index ]
1.6700 (estimate) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
pKa1 6.45; pKa2 8.8(at 25℃) | [color ]
Brown to reddish brown |
| Hazard Information | Back Directory | [Uses]
Nitracrine inhibits RNA synthesis and covalently, reversibly binds to DNA but also forms covalent adducts with DNA in vivo. Nitracrine, a 1-nitroacridine derivative, is a potent hypoxia-selective agent in vitro and antitumor agent. Nitracrine has cytotoxicity towards most cells[1][2][3]. | [Definition]
ChEBI: Nitracrine is a member of acridines. | [References]
[1] Wilson WR, et al. Selective toxicity of nitracrine to hypoxic mammalian cells. Br J Cancer. 1984 Feb;49(2):215-23. DOI:10.1038/bjc.1984.34
[2] Gniazdowski M, et al. Nitracrine and its congeners--an overview. Gen Pharmacol. 1995 May;26(3):473-81. DOI:10.1016/0306-3623(94)00143-b
[3] Daghastanli NA, et al. Cytotoxicity of nitroheterocyclic compounds, quinifuryl and nitracrine, towards leukaemic and normal cells on the dark and under illumination with visible light. J Photochem Photobiol B. 2004 Jul 19;75(1-2):27-32. DOI:10.1016/j.jphotobiol.2004.04.005 |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|